参考文献
[1]Mahlangu J, Cerquiera M, Srivastava A.Emerging therapies for haemophilia-Global perspective [J].Haemophilia, 2018,24(Suppl 6):15-21.
[2]Ling G, Nathwani A C, Tuddenham E G D.Recent advances in developing specific therapies for Haemophilia [J].British Journal of Haematology, 2018,18:161-172.
[3]Youg.G.How I treat children with Haemophilia and inhibitors [J].British Journal of Haematology,2019,186:400-408.
[4]Garagiola I, Palla R, Peyvandi F.Risk Factors for inhibitor development in severe hemophilia A [J].Thrombosis Research, 2018,168:20-27.
[5]Calvez T,Chambost H, D'Oiron R, et al.Analyses of the France Coag cohort support differences in immunogenicity among one plasmaderived and two recombinant factor Ⅷbrands in boys with severe hemophilia A [J].Haematologica, 2018,103(1):179-189.
[6]Lai J D, Lillicrap D.Factor FⅧ inhibitors:advances in basic and translational science [J].Int.J.Lab hematol, 2017,39(Suppl 1):6-13.
[7]Zerra P E, Cox C, Baldwin W H,et al.Marginal zone B cells are critical tofactor FⅧinhibitor formation inmice with hemophilia A [J].Blood, 2017,130:2559-2568.
[8]Spena S, Garagiola I, Cannavò A,et al.Prediction of Factor Ⅷ inhibitor development in the SIPPET cohort by mutational analysis and Factor Ⅷ antigenmeasurement [J].Journal of Thrombosis and Haemostasis, 2018,16(4):778-790.
[9]Peyvandi F, Cannavò A, Garagiola I, et al.Timing and severity of inbibitor development in recombinant versus.Plasma-derived factor Ⅷ concentrates:a SIPPET analysis [J].J Thromb Haemost, 2017,16:39-43.
[10]Hassan S, Cannavò A, Gouw.S C, et al.Factor Ⅷ products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A:a systematic review [J].Journal of Thrombosis and Haemostasis, 2018,16:1055-1068.(https://www.daowen.com)
[11]Franchini M,Marano G,Pati I, et al.Emicizumab for the treatment of Hemophilia A:a narrative review [J].Blood ransfus,2019,17:223-228.
[12]Cafuir L,Krus-Jarres R, Mancuso M E, et al.Emicizumab for hemophilia A without inhibitors [J].Expert Review of Hematology,2019,12(7):515-524.
[13]Yada K,Nogami K.Spotlight on Emicizumab in the management of hemophilia A:Patient selection and special considerations [J].Journal of blood Medicine,2019,10:171-181.
[14]Oldenburg J,Mahlangu J N,Bujan W, et al.The effect of emicizumab prophylaxis on health-related outcomes in persons with Haemophilia A with inhibitors:HAVEN 1 Study [J].Haemophilia,2019,25:33-44.
[15]Adamkewicz J I,Chen D C,Paz-priel I.Effects and Interferences of Emicizumab,a Humanised Bispecific Antibody Mimicking Activated Factor Ⅷ cofactor Function,on Coagulation Assays[J].Thromb Haemost,2019,119:1084-1093.
[16]Lippi G,Favaloro E J.Emicizumab(ACE 910):Clinical background and laboratory assessment of Hemophilia A [J].Advclinchem,2019,88:151-167.
[17]Ling G,Amit C,Nathwani,et al.Recent advances in developing specific therapies for Hemopilia[J].British Journal of Haematology,2018,181(2).
[18]Pasi K J, Rangarajan S, Georgiev P,et al.Targeting of antithrombin in hemophilia A or B with RNAi therapy [J].New England Journal of Medicine, 2017,377:819-828.
[19]Eichler H,Angchaisuksiri P,Kavakli K,et al.Concizumab restores thrombin generation Potential in patients with haemophilia:Pharmacokinetic/pharmacodynamic modeling results of cocizumab phase 1/1b data [J].Haemophilia,2019,25:60-66.
[20]Lauritzen B,Olling J,Abel K,et al.Administration of recombinant FⅦa(rFⅦa)to concizumab-dosed monkeys is safe,and cocizumab does not affect the potency of rFⅦa in hemophilic rabbits [J].J Thromb Haemost,2019,17:460-469.